Theraly’s mission is to develop innovative and revolutionary therapies for curing fibrotic diseases - including chronic pancreatitis, systemic sclerosis and NASH. The company’s lead candidate, TLY012, selectively targets myofibroblasts, cells believed to be the critical originators of fibrosis, a condition that affects a variety of tissues. By targeting these fundamental upstream mechanisms of fibrogenesis, we will provide a unique opportunity to develop curative therapies for multiple life-threatening fibrotic and autoimmune conditions.